期刊
MABS
卷 8, 期 8, 页码 1437-1455出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2016.1219005
关键词
Antibodies; clinical trials; immunotherapy; immune checkpoint; molecular-targeting; ovarian cancer; tumor-associated antigen; tumor-promoting molecule; vaccine
资金
- Cancer Research UK [C30122/A11527, C30122/A15774]
- Academy of Medical Sciences
- CR UK//NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Center [C10355/A15587]
- Medical Research Council [MR/L023091/1]
- CR UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Center [C1519/A10331]
- National Institute for Health Research (NIHR) Biomedical Research Center based at Guy's and St Thomas' NHS Foundation Trust and King's College London
- Academy of Medical Sciences (AMS) [AMS-SGCL10-Josephs] Funding Source: researchfish
- National Institute for Health Research [CL-2012-17-005] Funding Source: researchfish
- MRC [MR/L023091/1] Funding Source: UKRI
Antibody therapeutics against different target antigens are widely used in the treatment of different malignancies including ovarian carcinomas, but this disease still requires more effective agents. Improved understanding of the biological features, signaling pathways, and immunological escape mechanisms involved in ovarian cancer has emerged in the past few years. These advances, including an appreciation of the cross-talk between cancer cells and the patient's immune system, have led to the identification of new targets. In turn, potential antibody treatments with various mechanisms of action, including immune activation or toxin-delivery, that are directed at these targets have been developed. Here, we identify established as well as novel targets for antibodies in ovarian cancer, and discuss how they may provide fresh opportunities to identify interventions with enhanced therapeutic potential.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据